This article is more than 5 years old. Information may no longer be current.

Odds of familial hypercholesterolemia elevated in founder populations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTA ANA PUEBLO, N.M. — French-Canadian and Franco-American founder populations had increased risk for familial hypercholesterolemia, and may benefit from future research on prevention and intervention strategies, according to results from an analysis presented at the American Society for Preventive Cardiology Congress on CVD.

Reed Mszar, MPH candidate at Yale School of Public Health, and colleagues analyzed data from 231 patients (66% women) from the Central Maine Medical Center site of the CASCADE FH registry.

“We hope to utilize the FH Foundation’s registry to determine, generally speaking, the impact of FH on this Franco-American founder population,” Mszar said.

Variables that were examined included lipid levels, demographics, clinical features of FH, prior CV events and procedures, relevant comorbidities, reason for initial evaluation and treatments for FH.

Of the patients in this analysis, 47% identified as either French-Canadian or Franco-American. Over half of patients in this study had hypertension (53%), whereas 28% had CAD and 3% had HF.

Pre-treatment LDL was 241 mg/dL, which decreased to 125 mg/dL once patients were on treatment. Nearly 40% of patients with FH were able to reduce their LDL to less than 100 mg/dL, he said.

“Although these patients aren’t at the necessarily on-average or desired below 100 mg/dL, compared to national data, which say that on-treatment LDL is around 141 mg/dL, this group is relatively doing well so far,” Mszar said.

Previous medical histories of these patients showed 4% had a stroke, 18% had an MI and 3% had a transient ischemic attack prior to their entry into the registry.

Cascade screening and early medical interventions may have prevented these cardiac events, he said.

After the diagnosis of FH, 16% of patients underwent PCI and 12% underwent CABG.

“We hope that more patients and providers will be able to recognize a family history of premature CAD [and] high LDL cholesterol and we hope that those rates [of recognition] increase,” Mszar said. – by Darlene Dobkowski

Reference:

Mszar R, et al. Poster #107. Presented at: American Society for Preventive Cardiology Congress on CVD; July 27-29, 2018; Santa Ana Pueblo, New Mexico.